KENNETH S. GRAHAM,DANIEL DIX,ERIC FURFINE,KELLY FRYE
申请号：
PT11157965
公开号：
PT2364691E
申请日:
2007.06.14
申请国别(地区):
PT
年份:
2013
代理人:
摘要：
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence showing in SEQ ID No: 4 or amino acids 27-457 of SEQ ID No: 4.
